IL308731A - UROKINASE PLASMINOGEN RECEPTOR TARGETED RADIOPHARMACEUTICALS - Google Patents
UROKINASE PLASMINOGEN RECEPTOR TARGETED RADIOPHARMACEUTICALSInfo
- Publication number
- IL308731A IL308731A IL308731A IL30873123A IL308731A IL 308731 A IL308731 A IL 308731A IL 308731 A IL308731 A IL 308731A IL 30873123 A IL30873123 A IL 30873123A IL 308731 A IL308731 A IL 308731A
- Authority
- IL
- Israel
- Prior art keywords
- plasminogen activator
- urokinase plasminogen
- activator receptor
- targeted radiopharmaceutical
- radiopharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nuclear Medicine (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191499P | 2021-05-21 | 2021-05-21 | |
| US202163191506P | 2021-05-21 | 2021-05-21 | |
| PCT/US2022/030272 WO2022246210A1 (en) | 2021-05-21 | 2022-05-20 | Urokinase plasminogen activator receptor-targeted radiopharmaceutical |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308731A true IL308731A (en) | 2024-01-01 |
Family
ID=84140859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308731A IL308731A (en) | 2021-05-21 | 2022-05-20 | UROKINASE PLASMINOGEN RECEPTOR TARGETED RADIOPHARMACEUTICALS |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220378956A1 (https=) |
| EP (2) | EP4341296A4 (https=) |
| JP (2) | JP2024520180A (https=) |
| KR (1) | KR20240035757A (https=) |
| AU (2) | AU2022276444A1 (https=) |
| CA (1) | CA3223227A1 (https=) |
| IL (1) | IL308731A (https=) |
| MX (1) | MX2023013836A (https=) |
| WO (2) | WO2022246183A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024147853A1 (en) * | 2023-01-05 | 2024-07-11 | NorthStar Medical Technologies, LLC | Method for stacked elution of mother-daughter radionuclides |
| CN120712109A (zh) * | 2023-01-18 | 2025-09-26 | 库拉赛特股份公司 | 用于位点特异性uPAR靶向的放射性核素标记肽缀合物 |
| US20240412886A1 (en) * | 2023-06-07 | 2024-12-12 | NorthStar Medical Technologies, LLC | Liquid Deposition of Salts for Bombardment Target Preparation |
| WO2025207781A1 (en) * | 2024-03-26 | 2025-10-02 | Monopar Therapeutics Inc. | Antibody radioisotope constructs |
| WO2026019458A1 (en) * | 2024-07-19 | 2026-01-22 | Monopar Therpeutics, Inc | Squaramide bi-functional chelators and associated radiopharmaceuticals and methods of use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5334371A (en) * | 1988-07-20 | 1994-08-02 | Schering Aktiengesellschaft | Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI |
| RU2182022C1 (ru) * | 2001-05-24 | 2002-05-10 | Российская медицинская академия последипломного образования МЗ РФ | Способ лечения онкологических заболеваний щитовидной железы |
| CN101022830A (zh) * | 2004-05-25 | 2007-08-22 | 阿特努奥恩公司 | 抑制下游 u P A R相互作用并结合了尿激酶类纤溶酶原激发剂（ u P A）与其受体（ u P A R）的复合物的配位体：在诊断或治疗中的识别和用途 |
| KR20120064120A (ko) * | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| FR2883562B1 (fr) * | 2005-03-24 | 2009-02-27 | Guerbet Sa | Chelates lipophiles et leur utilisation en imagerie |
| DK2117571T3 (en) * | 2006-12-08 | 2017-05-08 | Monopar Therapeutics Inc | Urokinase-type plasminogen activator receptor epitope |
| LT4095130T (lt) * | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| ES2784684T3 (es) * | 2015-02-26 | 2020-09-29 | Sciencons AS | Soluciones de radiofármacos con propiedades ventajosas |
| WO2016191186A1 (en) * | 2015-05-22 | 2016-12-01 | Memorial Sloan Kettering Cancer Center | Systems and methods for determining optimum patient-specific antibody dose for tumor targeting |
| AU2017281940C1 (en) * | 2016-06-24 | 2024-11-07 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
| US11629201B2 (en) * | 2017-05-24 | 2023-04-18 | ITM Isotope Technologies Munich SE | PSMA-binding agents and uses thereof |
| IL293375A (en) * | 2019-12-03 | 2022-07-01 | Debiopharm Res & Manufacturing S A | reactive couplings |
| CA3182769A1 (en) * | 2020-06-15 | 2021-12-23 | Andrew P. Mazar | Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (upar) for treatment of severe covid-19 disease |
| WO2022123462A1 (en) * | 2020-12-09 | 2022-06-16 | 3B Pharmaceuticals Gmbh | Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof |
-
2022
- 2022-05-20 JP JP2024516731A patent/JP2024520180A/ja active Pending
- 2022-05-20 EP EP22805584.4A patent/EP4341296A4/en active Pending
- 2022-05-20 MX MX2023013836A patent/MX2023013836A/es unknown
- 2022-05-20 IL IL308731A patent/IL308731A/en unknown
- 2022-05-20 EP EP22805562.0A patent/EP4341265A4/en active Pending
- 2022-05-20 US US17/749,574 patent/US20220378956A1/en active Pending
- 2022-05-20 JP JP2023572230A patent/JP2024519970A/ja active Pending
- 2022-05-20 US US17/749,763 patent/US20220409751A1/en active Pending
- 2022-05-20 AU AU2022276444A patent/AU2022276444A1/en active Pending
- 2022-05-20 KR KR1020237044222A patent/KR20240035757A/ko active Pending
- 2022-05-20 CA CA3223227A patent/CA3223227A1/en active Pending
- 2022-05-20 AU AU2022276433A patent/AU2022276433A1/en active Pending
- 2022-05-20 WO PCT/US2022/030234 patent/WO2022246183A1/en not_active Ceased
- 2022-05-20 WO PCT/US2022/030272 patent/WO2022246210A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20220378956A1 (en) | 2022-12-01 |
| KR20240035757A (ko) | 2024-03-18 |
| EP4341296A1 (en) | 2024-03-27 |
| WO2022246183A1 (en) | 2022-11-24 |
| AU2022276444A1 (en) | 2023-12-21 |
| CA3223227A1 (en) | 2022-11-24 |
| WO2022246210A1 (en) | 2022-11-24 |
| EP4341265A4 (en) | 2025-07-23 |
| MX2023013836A (es) | 2024-01-11 |
| JP2024519970A (ja) | 2024-05-21 |
| US20220409751A1 (en) | 2022-12-29 |
| JP2024520180A (ja) | 2024-05-21 |
| EP4341265A1 (en) | 2024-03-27 |
| EP4341296A4 (en) | 2025-07-30 |
| AU2022276433A1 (en) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL308731A (en) | UROKINASE PLASMINOGEN RECEPTOR TARGETED RADIOPHARMACEUTICALS | |
| GB2605340B (en) | Base editing enzymes | |
| IL299760A (en) | Radiopharmaceuticals and methods | |
| PL4031547T3 (pl) | Inhibitory kalikreiny osoczowej i ich zastosowania | |
| CA213769S (en) | Work lounge | |
| GB2613271B (en) | Static mixer | |
| GB2588479B (en) | Shock and agitator tool | |
| GB2628952B (en) | Active magnetic ranging while drilling | |
| GB202007431D0 (en) | Cysteine protease | |
| EP4349168A4 (en) | PLANT ACTIVATOR POWDER | |
| IL284323A (en) | Modified urokinase plasminogen activator polypeptides and methods of use | |
| GB2700205B (en) | Base editing enzymes | |
| IL289732A (en) | A urokinase plasminogen activator receptor-targeting peptide | |
| IL304219A (en) | Parts for extending half-life and methods of using them | |
| GB2592449B (en) | Gyroscopic stabiliser | |
| CA207038S (en) | Rock slider | |
| GB201918112D0 (en) | Machine tools and methods of operation thereof | |
| GB202308798D0 (en) | Sestrin-mapk complex activators | |
| GB202309790D0 (en) | Novel reprogramming activators and methods | |
| GB202000208D0 (en) | Pak1 activators | |
| GB2598317B (en) | Gyroscopic stabiliser | |
| HK40095945A (en) | Modified serine protease proproteins | |
| GB202308197D0 (en) | Protease | |
| GB2597324B (en) | Horizontal directional drilling tool | |
| GB202017252D0 (en) | Planning in mobile robots |